Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1053-1063

  De Ruyck, Kim ^a   Nackaerts, Kristiaan ^b   Beels, Laurence ^a   Werbrouck, Joke ^a   De Volder, Annick ^c   Meysman, Marc ^d   Salhi, Bihiyga ^e   Van Meerbeeck, Jan ^e   Thierens, Hubert ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

CHRNA3; COMT; DRD2; nicotine dependence; polymorphism; smoking cessation; withdrawal

Indexed keywords

AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; NICOTINE PATCH; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3; TYROSINE; UNCLASSIFIED DRUG; VARENICLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; QUESTIONNAIRE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, GENETIC; QUESTIONNAIRES; RECEPTORS, DOPAMINE D2; RECEPTORS, NICOTINIC; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER; TRANSDERMAL PATCH; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955592801     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.75     Document Type: Article

References (63)

1. Armour BS, Woollery T, Malarcher A, Pechacek TF, Husten C: Annual smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 1997-2001. MMWR Morb. Mortal. Wkly Rep. 54, 625-628 (2005).
2. True WR, Heath AC, Scherrer JF et al.: Genetic and environmental contributions to smoking. Addiction 92(10), 1277-1287 (1997).
3. Lerman C, Caporaso NE, Audrain J et al.: Evidence suggesting the role of specifc genetic factors in cigarette smoking. Health Psychol. 18(1), 14-20 (1999).
4. Sullivan PF, Kendler KS: The genetic epidemiology of smoking. Nicotine Tob. Res. 1(Suppl. 2), S51-S57 (1999).
5. Li MD, Cheng R, Ma JZ, Swan GE: A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98(1), 23-31 (2003).
6. Munafo MR, Clark T, Johnstone E, Murphy MFG, Walton RT: The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob. Res. 6(4), 583-597 (2004).
7. Uhl GR, Liu Q, Drgon T, Johnson C, Walther D, Rose JE: Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet. 8(10), 10 (2007).
8. Uhl GR, Liu Q, Drgon T et al.: Molecular genetics of successful smoking cessation-convergent genome-wide association study results. Arch. Gen. Psychiatry 65(6), 683-693 (2008).
9. Berrettini W, Yuan X, Tozzi F et al.: a-5/a-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 13(4), 368-373 (2008).
10. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 3, CD006103 (2007).
11. Zeiger JS, Haberstick BC, Schlaepfer I et al.: The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco. Hum. Mol. Genet. 17(5), 724-734 (2008).
12. Mwenifumbo JC, Tyndale RF: Genetic variability in CYP2A6 and the pharmacogenetics of nicotine. Pharmacogenomics 8(10), 1385-1402 (2007).
13. Rossing MA: Genetic infuences on smoking: candidate genes. Environ. Health Perspect. 106(5), 231-238 (1998).
14. Galzi JL, Changeux JP: Neuronal nicotinic receptors-molecular organization and regulations. Neuropharmacology 34(6), 563-582 (1995).
15. Bierut LJ, Madden PAF, Breslau N et al.: Novel genes identifed in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 16(1), 24-35 (2007).
16. Weiss RB, Baker TB, Cannon DS et al.: A candidate gene approach identifes the CHRNA5-A3-B4 region as a risk factor for age dependent nicotine addiction. PLoS Genet. 4(7), E1000125 (2008).
17. Saccone SF, Hinrichs AL, Saccone NL et al.: Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16(1), 36-49 (2007).
18. Thorgeirsson TE, Geller F, Sulem P et al.: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452(7187), 638-642 (2008).
19. Chen XN, Chen JC, Williamson VS et al.: Variants in nicotinic acetylcholine receptors a5 and a3 increase risks to nicotine dependence. Am. J. Med. Genet. B 150B(7), 926-933 (2009).
20. Saccone NL, Wang JC, Breslau N et al.: The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 69(17), 6848-6856 (2009).
21. Stevens VL, Bierut LJ, Talbot JT et al.: Nicotinic receptor gene variants infuence susceptibility to heavy smoking. Cancer Epidemiol. Biomarkers Prev. 17(12), 3517-3525 (2008).
22. Spitz MR, Amos CI, Dong Q, Lin J, Wu X: The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J. Natl Cancer Inst. 100(21), 1552-1556 (2008).
23. Caporaso N, Gu FY, Chatterjee N et al.: Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE 4(2), E4653 (2009).
24. Bierut LJ: Convergence of genetic fndings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends Pharmacol. Sci. 31(1), 46-51 (2010).
25. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P: Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav. Pharmacol. 20(1), 1-17 (2009).
26. Munafo MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA: Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob. Res. 11(1), 64-76 (2009).
27. Neville MJ, Johnstone EC, Walton RT: Identifcation and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23. Hum. Mutat. 23(6), 540-545 (2004).
28. Arinami T, Gao M, Hamaguchi H, Toru M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6(4), 577-582 (1997).
29. Duan JB, Wainwright MS, Comeron JM et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12(3), 205-216 (2003).
30. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M: Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 10(3), 527-530 (1991).
31. Huang WH, Payne TJ, Ma JZ et al.: Signifcant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacology 34(2), 319-330 (2009).
32. Connor JP, Young RM, Lawford BR, Saunders JB, Ritchie TL, Noble EP: Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism. Addict. Behav. 32(2), 310-319 (2007).
33. Timberlake DS, Haberstick BC, Lessem JM et al.: An association between the DAT1 polymorphism and smoking behavior in young adults from the national longitudinal study of adolescent health. Health Psychol. 25(2), 190-197 (2006).
34. Swan GE, Valdes AM, Ring HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion. Pharmacogenomics J. 5(1), 21-29 (2005).
35. Johnstone EC, Yudkin P, Griffths SE, Fuller A, Murphy M, Walton R: The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population. Addict. Biol. 9(3-4), 221-226 (2004).
36. Batra A, Gelfort G, Bartels M et al.: The dopamine D2 receptor (DRD2) gene-a genetic risk factor in heavy smoking? Addict. Biol. 5(4), 429-436 (2000).
37. Singleton AB, Thomson JR, Morris CM, Court JA, Lloyd S, Cholerton S: Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 8(2), 125-128 (1998).
38. Spitz MR, Shi HH, Yang F et al.: Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J. Natl Cancer Inst. 90(5), 358-363 (1998).
39. Gilbert DG, Zuo Y T, Rabinovich NE, Riise H, Needham R, Huggenvik JI: Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. J. Abnormal Psychol. 118(2), 322-334 (2009).
40. Munafo MR, Johnstone EC, Murphy MFG, Aveyard P: Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob. Res. 11(4), 404-407 (2009).
41. Johnstone EC, Yudkin PL, Hey K et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14(2), 83-90 (2004).
42. Yudkin P, Munafo M, Hey K et al.: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328(7446), 989-990 (2004).
43. Robinson JD, Lam CY, Minnix JA et al.: The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J. 7(4), 266-274 (2007).
44. Lerman C, Jepson C, Wileyto EP et al.: Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31(1), 231-242 (2006).
45. Chen JS, Lipska BK, Halim N et al.: Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75(5), 807-821 (2004).
46. Beuten J, Payne TJ, Ma JZ, Li MD: Signifcant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 31(3), 675-684 (2006).
47. Redden DT, Shields PG, Epstein L et al.: Catechol-O-methyl-transferase functional polymorphism and nicotine dependence: an evaluation of nonreplicated results. Cancer Epidemiol. Biomarkers Prev. 14(6), 1384-1389 (2005).
48. Colilla S, Lerman C, Shields PG et al.: Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet. Genomics 15(6), 393-398 (2005).
49. Munafo MR, Johnstone EC, Guo B, Murphy MFG, Aveyard P: Association of COMT Val(108/158)Met genotype with smoking cessation. Pharmacogenet. Genomics 18(2), 121-128 (2008).
50. (108/158)Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 16(6), 1065-1069 (2007).
51. Chandler MA, Rennard SI: Smoking cessation. Chest 137(2), 428-435 (2010).
52. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL: Nicotinic acetylcholine receptor b 2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol. Biomarkers Prev. 18(10), 2608-2612 (2009).
53. McKinney EF, Walton RT, Yudkin P et al.: Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics 10(6), 483-491 (2000).
54. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 86, 1119-1127 (1991).
55. Patten CA, Martin JE: Measuring tobacco withdrawal: a review of self-report questionnaires. J. Subst. Abuse 8(1), 93-113 (1996).
56. Rigotti NA, Munafo MR, Stead LF: Smoking cessation interventions for hospitalized smokers-a systematic review. Arch. Intern. Med. 168(18), 1950-1960 (2008).
57. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ: Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 48(7), 648-654 (1991).
58. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J: C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affnity. Synapse 63(10), 907-912 (2009).
59. Bierut LJ, Stitzel JA, Wang JC et al.: Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiat. 165(9), 1163-1171 (2008).
60. Breitling LP, Dahmen N, Mittelstrass K et al.: Smoking cessation and variations in nicotinic acetylcholine receptor subunits a-5, a-3, and b-4 genes. Biol. Psychiat. 65(8), 691-695 (2009).
61. Conti DV, Lee W, Li DL et al.: Nicotinic acetylcholine receptor b 2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum. Mol. Genet. 17(18), 2834-2848 (2008).
62. Freathy RM, Ring SM, Shields B et al.: A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum. Mol. Genet. 18(15), 2922-2927 (2009).
63. Baker TB, Weiss RB, Bolt D et al.: Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob. Res. 11(7), 785-796 (2009).